Addressing Acquired Resistance by Predicting Clinical Trial Outcomes & Improving Patient Response Rates
Time: 11:30 am
day: Workshop D
Details:
Acquired resistance to mutant-selective RAS inhibitors, including approved and investigational KRAS G12C inhibitors, presents significant challenge. It is critical that we not only consider the efficacy of direct inhibitor targeting but debate how additional drugging of vertical pathways can be crucial to overcoming feedback mechanisms. As recent advances in the last six months have uncovered novel mechanisms of RAS inhibitor resistance, this workshop will deep-dive into how we can improve patient response rates with genomic and biomarker data.
This workshop will discuss:
• How to identify and characterize mechanisms underlying RAS acquired resistance
• How to predict clinical trial outcomes before the clinic considering tumor heterogeneity
• How to develop predictive biomarkers for identifying patients at risk of resistance
• How to optimize the dosing and scheduling of single or combination therapies to delay or overcome resistance
